← Leaderboards
Amrita Basu Somani
University Of California, San Francisco
$1,497,160
Attributed
$1,497,160
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $407.3K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,497,160 · 2
By mechanism
R01$1,089,822 · 1
R21$407,338 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Diane V Havlir$125,216,731
- Daniel B Vigneron$43,424,992
- William A Weiss$31,543,847
- Jon David Levine$42,152,746
- Monica Gandhi$27,077,063
Others in their field
Other Emerging Leaders on “Patient Outcomes Assessments”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Abraham Aizer Brody · New York University School Of Medicine$40,786,286
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Klaus Romero · Critical Path Institute$29,190,596
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
Research focus
Patient Outcomes AssessmentsSeveritiesMachine LearningParticipantQuality Of LifeReportingData ReportingHigh RiskMethodologyNeoadjuvant TherapyPredictive ModelingProspectiveCancer Clinical TrialAlgorithmsCaringAdverse EventEventHealth Related Quality Of LifeAffectMalignant Breast NeoplasmBreastMonitorPharmaceutical PreparationsSite
Grant awards (4)
Analyzing Patient-Level Data in a Breast Cancer Clinical Trial$369,431
R01 · FY2025 · CA · contact PI
Analyzing Patient-Level Data in a Breast Cancer Clinical Trial$350,960
R01 · FY2024 · CA · contact PI
Analyzing Patient-Level Data in a Breast Cancer Clinical Trial$369,431
R01 · FY2023 · CA · contact PI
Predicting the Likelihood of Immune-related Adverse Events in Breast Cancer Patients$407,338
R21 · FY2021 · CA · contact PI